Cash-strapped Santaris soldiers on
The cash pool in Santaris Pharma is steady dwindling, but there are a range of solutions available to the management in their efforts to steer the Danish biotech company safely through the capital drought.
af LEONORA BECK
The Santaris management describes the current year and the future of the biotech company in very hopeful terms. Despite the fact that liquid assets at the close of 2011 had shrunk to a mere DKK 54.9 million compared with 124.5 million in 2010, which dropped the cash pool to its lowest level since 2005.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Santaris-chairman: Major loan to ensure survival
For abonnenter
